Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: Results of a phase II trial

Anti-Cancer Drugs

Volumn 16, Issue 4, 2005, Pages 435-440

  Gnad Vogt, Senta Ulrike ^a   Hofheinz, Ralf Dieter ^a   Saussele, Susanne ^a   Kreil, Sebastian ^a   Willer, Andreas ^a   Willeke, Frank ^b   Pilz, Lothar ^c   Hehlmann, Rüdiger ^a   Hochhaus, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

5 fluorouracil; Gastric cancer; Mitomycin C; Pegylated liposomal doxorubicin

Indexed keywords

CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CLEMASTINE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; ONDANSETRON; TROPISETRON; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; FEBRILE NEUTROPENIA; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; NAUSEA; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PLEURA METASTASIS; PRIORITY JOURNAL; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOMYCIN; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 15944411781     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200504000-00010     Document Type: Article

References (17)

1. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587-591.
2. Glimelius B, Ekstrom K, Hoffmann K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163-168.
3. Vanhoefer U, Rougier P, Wilke H-J, Ducreux MP, Lacave AJ, van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group. J Clin Oncol 2000; 18:2648-2657.
4. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, et al. A phase II study in advanced gastrooesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5:609-616.
5. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15:261-267.
6. Wilke H, Korn M, Vanhofer U, Fink U, Stahl M, Preusser P, et al. Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. J Infus Chemother 1996; 6:123-126.
7. Stahl M, Vanhoefer U, Fink U, Korn M, Eigler FW, Siewert JR, et aL Phase II study of weekly high-dose 5-fluorouracil and folinic acid plus biweekly alternating cisplatin and epirubicin (FUFACE) in patients with advanced gastric carcinoma. Onkologie 1996; 19:416-418.
8. Kretzschmar A, Reichhardt P, Thuss-Patience PC, Hohenberger P, Benter T, Dorken B, et al. Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. Oncology 2000; 59:14-17.
9. Hofheinz R, Hartung G, Samel S, Hochhaus A, Pichlmeier U, Post S, et al. High-dose 5-fluorouracil/folinic acid in combination with three-weekly mitomycin C in treatment of advanced gastric cancer. A phase II study. Onkologie 2002; 25:255-260.
10. Hartmann JT, Quietzsch D, Wein A, Hofheinz R, Oechsle K, Honecker F, et al. Protracted infusional 5-fluorouracil plus high dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer 2003; 89:2051-2056.
11. Macdonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, et al. 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93:533-536.
12. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicine-a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9:827-831.
13. Hofheinz RD, Willer A, Weisser A, Gnad U, Saussele S, Kreil S, et al. Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase I study in patients with upper gastrointestinal cancer. Br J Cancer 2004; 90:1893-1897.
14. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized controlled trials using individual patient data. J Clin Oncol 2004; 22:2395-2402.
15. Vanhoefer U, Wagner T, Lutz M, Van Cutsem E, Nordlinger B, Reuse S, et al. Randomized phase II study of weekly 24 h infusion of high dose 5-FU ± folinic acid (HD-FU/FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC trial 40953. Eur J Cancer 2001; 7(suppl 6):88 (abstr).
16. Ajani JA, van Cutsem E, Moiseyenko V, Tjulandin S, Fodor N, Majlis A, et al. Docetaxel, cisplatin, 5-fluorouracil compared to cisplatin and 5-fluorouracil for chemotherapy-naive patients with metastatic or locally recurrent unresectable gastric carcinoma: interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003; 22:999 (abstr).
17. Roth AD, Maibach R, Falk S, Stupp R, Saletti P, Käberle D, et al. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss group for clinical cancer research (SAKK). Proc Am Soc Clin Oncol 2004; 23:4020 (abstr).